Fast walking prevents prostate cancer

The study of 1455 male patients, diagnosed with early prostate cancer, the researchers found: The minimum brisk walking: 4.83 km per hour, 3 hours per week (ie 14.49 km per week will lower the risk of developing prostate cancer , according to scientists at the University of California, San Francisco, USA and Harvard School of Public Health.

Scientists found that: Male patients were diagnosed with early prostate cancer after practicing walking at least 4.83 km per hour, and at least three hours per week, As a result, nearly 60% of these male patients are less likely to develop cancer recurring signs of cancer or to treat prostate cancer in the second stage.

" It is important that the intensity of physical activity, walking must be fast enough that these patients will achieve the expected treatment results ," said Erin Richman, a graduate student at UCSF University. United States, the first author of this study. The results of this study were published in the May 24, 2011 issue of Cancer Research. "Research results provide prostate cancer patients with how they can do to improve the disease. their own love. "

PhD student Erin Richman

Previous research, published in early 2011, by June Chan of UCSF University, USA and colleagues at the Harvard School of Public Health, showed that physical activity after the diagnosis of Patients with prostate cancer will work to reduce mortality in men with this disease . The new study complements this discovery, as it is the first study to focus on the effectiveness of physical activity after a diagnosis of the initial signs of developing prostate cancer, for example. as there is an increase in prostate-specific antigen in the blood (PSA).

" Our research shows that strong physical activity or brisk walking may have benefits in the early stages of prostate cancer ," said Professor Chan, who works at UCSF University in the United States. period and the main author of both studies.

In the United States, prostate cancer is one of the two most common cancers diagnosed in men, second only to skin cancer, and there are more than 217,000 male patients diagnosed with cancer. Prostate every year, according to the US National Cancer Institute. In 2010 alone, 32,050 men died of prostate cancer.

Strong physical activity or brisk walking always bring significant benefits and help improve cardiovascular, diabetic and other health conditions. Previous research has also shown the benefits of regular physical activity, reflected in positive results in treating breast and colon cancer, but this is one of the first studies to prove beneficial. Such benefits are for men with prostate cancer.

The study participants were selected as a subset of a larger group of 14,000 men with prostate cancer that were enrolled in a long-term study of prostate cancer control nationwide. The so-called prostate cancer treatment strategy test, led by Dr. Peter Carroll, chairman of the Department of Urology, UCSF University, USA and the author of this study.

What's interesting about the study is the focus on preventing the recurrence of early prostate cancer, which occurs before the patient can experience painful symptoms of adenocarcinoma. Prostate, a frequent cause for men to reduce their normal physical activity. In addition, the researcher also argued that the benefits of physical activity are completely independent of the age of the patient, the type of treatment and the clinical characteristics of the disease.

Fast walking useful for everyone (Photo: Nytimes)

When asked if the doctor will recommend walking therapy for all men diagnosed with prostate cancer, Dr. Chan stressed: Quick walking .

" The results of the study suggest that it is important that when you are involved in exercise, move your heartbeat a little faster ," Dr. Chan said.

Article, " Physical activity after diagnosis and the risk of prostate cancer progresses: Data from the experimental urological treatment strategy for prostate cancer " by the authors: Erin L . Richman, Stacey A. Kenfield, Meir J. Stampfer, Alan Paciorek, Peter R. Carroll and June M. Chan

The research was funded by the Department of Defense, Prostate Cancer Fund, Abbott Laboratory and the US National Institutes of Health training grant.